Tumor Fibroblast-Derived FGF2 Regulates Expression of SPRY1 in Esophageal Tumor-Infiltrating T Cells and Plays a Role in T-cell Exhaustion.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33093168.
- Also identified by DOI 10.1158/0008-5472.CAN-20-1542.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T-cell exhaustion was initially identified in chronic infection in mice and was subsequently described in humans with cancer. Although the distinct signature of exhausted T (T<sub>EX</sub>) cells in cancer has been well investigated, the molecular mechanism of T-cell exhaustion in cancer is not fully understood. Using single-cell RNA sequencing, we report here that T<sub>EX</sub> cells in esophageal cancer are more heterogeneous than previously clarified. Sprouty RTK signaling antagonist 1 (SPRY1) was notably enriched in two subsets of exhausted CD8<sup>+</sup> T cells. When overexpressed, SPRY1 impaired T-cell activation by interacting with CBL, a negative regulator of ZAP-70 tyrosine phosphorylation. Data from the Tumor Immune Estimation Resource revealed a strong correlation between FGF2 and SPRY1 expression in esophageal cancer. High expression of FGF2 was evident in fibroblasts from esophageal cancer tissue and correlated with poor overall survival. <i>In vitro</i> administration of FGF2 significantly upregulated expression of SPRY1 in CD8<sup>+</sup> T cells and attenuated T-cell receptor-triggered CD8<sup>+</sup> T-cell activation. A mouse tumor model confirmed that overexpression of FGF2 in fibroblasts significantly upregulated SPRY1 expression in T<sub>EX</sub> cells, impaired T-cell cytotoxic activity, and promoted tumor growth. Thus, these findings identify FGF2 as an important regulator of SPRY1 expression involved in establishing the dysfunctional state of CD8<sup>+</sup> T cells in esophageal cancer. SIGNIFICANCE: These findings reveal FGF2 as an important regulator of SPRY1 expression involved in establishing the dysfunctional state of CD8<sup>+</sup> T cells and suggest that inhibition of FGF2 has potential clinical value in ESCC. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/24/5583/F1.large.jpg.
Medical subject headings
- Adaptor Proteins, Signal Transducing
- CD8-Positive T-Lymphocytes
- Cancer-Associated Fibroblasts
- Esophageal Neoplasms
- Fibroblast Growth Factor 2
- Lymphocytes, Tumor-Infiltrating
- Membrane Proteins
- Phosphoproteins